United States

Photocure ASA (PHO.OL)

PHO.OL on Oslo Stock Exchange

23 Mar 2017
Change (% chg)

kr0.50 (+1.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Photocure Q3 EBITDA loss stable at 1.6 million crowns
Tuesday, 15 Nov 2016 01:40am EST 

Photocure ASA : Reported a revenue growth of 17 pct to 31.6 million Norwegian crowns ($3.7 million) in Q3 of 2016 (Q3 2015: 27.0 million crowns) for Hexvix/Cysview commercial franchise . Q3 EBITDA loss of 1.6 million crowns versus loss 1.6 million crowns year ago . Reported total revenues of 35.2 million crowns in Q3 of 2016 versus 35.9 million year ago .Expects Hexvix/Cysview unit sales growth rates to be approximately 5 pct for the year.  Full Article

Photocure: Hexvix marketing authorization approval in Australia
Wednesday, 24 Aug 2016 03:52am EDT 

Photocure ASA : Says partner, Juno Pharmaceuticals Pty Ltd, has received marketing authorization approval (MAA) for Hexvix in Australia .Will receive 250,000 euros in milestone payments.  Full Article

Photocure Q2 operating loss widens to NOK 4.4 million
Tuesday, 23 Aug 2016 01:35am EDT 

Photocure ASA : Q2 sales revenue 34.2 million Norwegian crowns versus 28.9 million crowns year ago . Q2 operating loss 4.4 million crowns versus loss 1.9 million crowns year ago . Expects to increase unit sales growth rates for Hexvix/Cysview . Says is entitled to receive 4 million euros from Galderma in Q4 as final payment related to 2009 Metvix asset purchase agreement .Cash position is expected to remain solid throughout 2016 including committed deferred payments and milestones.  Full Article

Photocure: Cysview granted FDA approval of new prefilled syringe
Thursday, 11 Aug 2016 02:00am EDT 

Photocure ASA :U.S. Food & Drug Administration has granted approval for an improved packaging for Cysview.  Full Article

Photocure Q1 operating loss narrows to NOK 4.9 mln
Tuesday, 10 May 2016 01:30am EDT 

Photocure ASA : Q1 sales revenue 33.5 million Norwegian crowns ($4.07 million) versus 28.4 million crowns year ago . Q1 operating loss 4.9 million crowns versus loss 7.2 million crowns year ago . Expects increasing unit sales growth rates for Hexvix/Cysview through continued positive sales development of Cysview in the US .To expand its commercial presence in urology by furthering Hexvix/Cysview opportunity in bladder cancer surveillance market with finilization on new phase 3 clinical trial.  Full Article

PhotoCure ASA: analysis shows Hexvix/Cysview significantly prolongs time to progression of bladder cancer
Tuesday, 26 Apr 2016 02:01am EDT 

PhotoCure ASA:New analysis shows Hexvix/Cysview significantly prolongs time to progression of bladder cancer.Says using the new IBCG definition, overall time to disease progression was significantly longer in the BLC with Hexvix/Cysview group (p=0.05).Says new analysis of a long term follow-up study classified patients according to the new International Bladder Cancer Group (IBCG) definition of disease progression.Says Hexvix/Cysview is a photosensitizing agent taken up selectively by the tumor cells in the bladder that when exposed to blue light during a cystoscopic procedure results in a bright pink fluorescence of the suspicious tissue.  Full Article

PhotoCure new patent for Cevira granted in Europe
Tuesday, 15 Mar 2016 03:00am EDT 

PhotoCure ASA:New patent for Cevira has been granted in Europe.The newly granted patent protects the Cevira drug, its use and its combination with a drug delivery device, such as the Cevira device, until 2030.  Full Article

PhotoCure ASA announces grant of new European patent for Cevira
Tuesday, 22 Sep 2015 02:09am EDT 

PhotoCure ASA:Announces that a new patent for Cevira has been granted in Europe.Says newly granted patent protects Cevira device including its use in combination with Cevira drug until 2029.  Full Article

PhotoCure ASA announces BioSyent Pharma exclusive partner for Cysview in Canada
Wednesday, 19 Aug 2015 02:30am EDT 

PhotoCure ASA:Announces appointment of BioSyent Pharma Inc. as their exclusive distributor for the commercialization of Cysview in Canada.Cysview/Hexvix is Photocure's flagship product to aid in the diagnosis and management of bladder cancer.Under the terms of the agreement, Photocure will receive up to $1,000,000 in milestone payments for the rights to Cysview in the territory, which includes $650,000 upon signing of the agreement.BioSyent Pharma will fund all costs related to the launch and commercialization of Cysview, which was approved by Health Canada in Jan. 2015.  Full Article

PhotoCure maintains FY 2015 outlook
Thursday, 13 Aug 2015 01:40am EDT 

PhotoCure ASA:Expects revenues to continue to grow in FY 2015 driven by an increase of Hexvix/Cysview in-market unit sales of at least 10 pct.Reported revenue of 93.6 million Norwegian crowns for FY 2014.  Full Article

More From Around the Web

BRIEF-Photocure Q4 EBITDA loss narrows to NOK 0.3 million

* Q4 total revenue 38.1 million Norwegian crowns ($4.5 million) versus 34.5 million crowns year ago